Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST
Company Participants
Susie Lisa – Senior Vice President of Investor Relations
Reshma Kewalramani – CEO, President & Director
Stuart Arbuckle
Charles Wagner – Executive VP, COO & CFO
Duncan J. McKechnie – Chief Commercial Officer, Head of North America Commercial & Executive VP
Conference Call Participants
Geoffrey Meacham – Citigroup Inc., Research Division
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Tazeen Ahmad – BofA Securities, Research Division
Brian Abrahams – RBC Capital Markets, Research Division
Terence Flynn
Philip Nadeau – TD Cowen, Research Division
Huidong Wang – Barclays Bank PLC, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
William Pickering – Sanford C. Bernstein & Co., LLC., Research Division
Presentation
Operator
Good day, and welcome to the Vertex Pharmaceuticals Third Quarter 2025 Earnings Call. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead, ma’am.
Susie Lisa
Senior Vice President of Investor Relations
Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our third quarter 2025 financial results conference call. On tonight’s call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex’s CEO and President; Duncan McKechnie, Chief Commercial Officer; and Charlie Wagner, Chief Operating and Financial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today’s press release and in our filings with the
